礼来Taltz(依奇珠单抗)与Zepbound(替尔泊肽)联合疗法在银屑病合并肥胖或超重成人患者的首创3B期试验中展现卓越疗效

美股速递
Feb 18

在一项针对银屑病合并肥胖或超重成人患者的首创3B期临床试验中,礼来公司的Taltz(依奇珠单抗)与Zepbound(替尔泊肽)联合使用展现出卓越的治疗效果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10